Dietary Supplement
Ionic Minerals Research
The following research abstracts
are presented to reflect the findings of possible benefits from
minerals as a dietary supplement and nutritional supplement.
For more information on individual minerals, please visit the
ionic minerals page.
Prostate Cancer Research
1) Early
stage prostate cancer treated with radiation therapy: Stratifying
an intermediate risk group
2) Enhancement
of prostate tumor volume definition with intravesical contrast:
A three-dimensional dosimetric evaluation
3) Arachidonic
acid stimulates prostate cancer cell growth: Critical role of
5-lipoxygenase
4) Induction
of cyclo-oxygenase-2 mRNA by prostaglandin E-2 in human prostatic
carcinoma cells.
5) Mitoxantrone:
A review of its pharmacology and clinical efficacy in the management
of hormone-resistant advanced prostate cancer.
6) Molecular
and cellular biology of prostate cancer.
7) Antiproliferative
effect of Pygeum africanum extract on rat prostatic fibroblasts.
8) Flutamide
withdrawal plus hydrocortisone resulted in clinical complete
response in a patient with prostate carcinoma.
9) Quality
of life and treatment outcomes: Prostate carcinoma patients'
perspectives after prostatectomy or radiation therapy.
10) Prostate
cancer detection in men with serum PSA concentrations of 2.6
to 4.0 ng/mL and benign prostate examination: Enhancement of
specificity with free PSA measurements.
11) Comparison
of percent free prostate specific antigen and prostate specific
antigen density as methods to enhance prostate specific antigen
specificity in early prostate cancer detection in men with normal
rectal examination and prostate specific antigen between 4.1
and 10 ng/ml
12) Prevalence
and predictors of a positive repeat transrectal ultrasound guided
needle biopsy of the prostate
13) Accelerated
tumor proliferation rates in locally recurrent prostate cancer
after radical prostatectomy
14) Improved
survival in patients with locally advanced prostate cancer treated
with radiotherapy and goserelin
15) Prostate
cancer: Relative effects of demographic, clinical, histologic,
and MR imaging variables on the accuracy of staging
16) Results
of 3D conformal radiotherapy in the treatment of localized prostate
cancer
17) Induction
of apoptosis and altered nuclear/cytoplasmic distribution of
the androgen receptor and prostate-specific antigen by 1 alpha,25-dihydroxyvitamin
D-3 in androgen-responsive LNCaP cells
18) Effects
of endocrine therapy on the primary lesion in patients with
prostate carcinoma as evaluated by endorectal magnetic resonance
imaging
19) Ischemic
damage to the prostate during cardiac surgery: A clinical model
20) Prostate-specific
antigen-detected prostate cancer (stage T1c): an analysis of
whole-mount prostatectomy specimens.
21) Prostate-specific
antigen failure despite pathologically organ-confined and margin-negative
prostate cancer: The basis for an adjuvant therapy trial.
22) Family
history of prostate cancer in patients with localized prostate
cancer: An independent predictor of treatment outcome.
23) Phase
II trial of suramin, leuprolide, and flutamide in previously
untreated metastatic prostate cancer.
24) The
antiandrogen withdrawal syndrome.
